Switch theme
Sign up to access all valuation multiples
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
2020
80
Last FY Revenue n/a
LTM EBITDA -$100M
-$61.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ALX Oncology has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$100M.
In the most recent fiscal year, ALX Oncology achieved revenue of n/a and an EBITDA of -$132M.
ALX Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ALX Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$100M | XXX | -$132M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$124M | XXX | -$142M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$124M | XXX | -$135M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ALX Oncology's stock price is $0.
ALX Oncology has current market cap of $25.9M, and EV of -$61.9M.
See ALX Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$61.9M | $25.9M | XXX | XXX | XXX | XXX | $-2.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ALX Oncology has market cap of $25.9M and EV of -$61.9M.
ALX Oncology's trades at n/a EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate ALX Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ALX Oncology has a P/E ratio of -0.2x.
See valuation multiples for ALX Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25.9M | XXX | $25.9M | XXX | XXX | XXX |
| EV (current) | -$61.9M | XXX | -$61.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialALX Oncology's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
ALX Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ALX Oncology's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ALX Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | -29% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ALX Oncology acquired XXX companies to date.
Last acquisition by ALX Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . ALX Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ALX Oncology founded? | ALX Oncology was founded in 2020. |
| Where is ALX Oncology headquartered? | ALX Oncology is headquartered in United States of America. |
| How many employees does ALX Oncology have? | As of today, ALX Oncology has 80 employees. |
| Who is the CEO of ALX Oncology? | ALX Oncology's CEO is Mr. Jason Lettmann. |
| Is ALX Oncology publicy listed? | Yes, ALX Oncology is a public company listed on NAS. |
| What is the stock symbol of ALX Oncology? | ALX Oncology trades under ALXO ticker. |
| When did ALX Oncology go public? | ALX Oncology went public in 2020. |
| Who are competitors of ALX Oncology? | Similar companies to ALX Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ALX Oncology? | ALX Oncology's current market cap is $25.9M |
| Is ALX Oncology profitable? | Yes, ALX Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ALX Oncology? | ALX Oncology's last 12 months EBITDA is -$100M. |
| What is the current EV/EBITDA multiple of ALX Oncology? | Current EBITDA multiple of ALX Oncology is 0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
